SNIPR BIOME Secures EUR 35 Million Series B Financing
SNIPR Biome ApS, a leading player in the field of microbial CRISPR-medicine, has successfully raised EUR 35 million in its latest Series B financing round. This significant investment involves contributions from both new and existing investors, showcasing confidence in the company's innovative approach.
Funding Sources and Purpose
The recent fundraising was bolstered by the support of notable organizations including the Cystic Fibrosis Foundation and Germany's Federal Agency for Breakthrough Innovation (SPRIN-D). Other backing came from established investors such as Lundbeckfonden BioCapital, North-East Family Office, and Wellington Partners.
Focus on Combatting Antimicrobial Resistance
This infusion of funds will play a crucial role in advancing the development of SNIPR’s CRISPR-Cas therapy aimed specifically at eliminating airway infections caused by Pseudomonas aeruginosa, particularly in patients suffering from cystic fibrosis. Moreover, it will facilitate further investigations into a microbial intervention designed to eradicate antibiotic resistance genes present in various bacterial strains.
Advancements in Clinical Trials
In addition to pioneering cures for targeted infections, the funding will expedite clinical trials for the company's flagship CRISPR product, SNIPR001. This product is currently under evaluation in a Phase 1b clinical study focusing on patients with hematologic cancers.
CEO's Vision and Commitment
Christian Grøndahl, the Chief Executive Officer and Co-Founder of SNIPR BIOME, articulated the importance of this financial backing. He noted that this financing stage represents a significant milestone in their journey to mitigate bloodstream infections and expand their pipeline dedicated to infectious diseases that pose critical health threats.
Innovative Approach to CRISPR Technology
SNIPR BIOME is distinct in its application of CRISPR-Cas technology, which enables ultra-targeted and rapid eradication of specific bacteria while preserving the surrounding healthy microbial community within patients. This innovative technology design facilitates the selective generation of therapeutics in targeted areas of the gastrointestinal tract.
Unique Position in the Biotechnology Landscape
The company stands out as a pioneer in its field, being the first to administer a CRISPR therapeutic orally to humans and securing patents in both the US and Europe for utilizing CRISPR to target microbiomes. This unique position underscores SNIPR BIOME's commitment to leading advancements in medical science.
Collaborative Efforts and Future Prospects
SNIPR BIOME collaborates with renowned organizations such as CARB-X, the Gates Foundation, and MD Anderson Cancer Center, reflecting its active role in the global fight against infectious diseases. The continued development of its CRISPR technology generates hope for addressing challenging health conditions, paving the way for future therapeutics.
About SNIPR BIOME
Based in Denmark, SNIPR Biome is a clinical-stage biotech company at the forefront of CRISPR-medicine development. Through innovative approaches to precision killing and gene modifications, the company aims to revolutionize treatments for various human diseases.
Media Contact
For more inquiries, contact Christian Grøndahl at +45 2020 2747 or via email at cg@sniprbiome.com.
Frequently Asked Questions
1. What is SNIPR BIOME known for?
SNIPR BIOME is recognized for its pioneering work in microbial CRISPR-medicine and innovative therapies aimed at combating infectious diseases.
2. How much funding did SNIPR BIOME raise?
SNIPR BIOME successfully raised EUR 35 million in a Series B financing round.
3. What will the funding be used for?
The funding will support the development of therapies targeting infections and the ongoing clinical trials for its product SNIPR001.
4. Who are SNIPR BIOME's collaborators?
They collaborate with various organizations, including CARB-X and the Gates Foundation.
5. What future prospects does SNIPR BIOME have?
SNIPR BIOME aims to expand its therapeutic pipeline and continue addressing antimicrobial resistance through innovative CRISPR technology.
